DelMar Pharmaceuticals recently presented a poster on dianhydrogalactitol at the Society for Neuro-Oncology's 4th Pediatric Neuro-Oncology Basic and Translational Research Conference, which took place at the Wyndham New Yorker Hotel in New York City in June.
Dianhydrogalactitol (VAL-083) is a DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. It has shown positive results in clinical trials sponsored by the U.S. National Cancer Institutes when used to treat various cancers.
"DelMar Pharmaceuticals is excited to share the promising horizon that VAL-083 results have shown in the treatment of pediatric brain tumor," Jeffrey Bacha, chairman and CEO of DelMar, said. "We are conscious of the difference VAL-083 could make in the lives of patients and their families, and we are driven by the determination of improving patient outcomes. We are confident that our research efforts will make an impactful contribution to the community and this area of science."
DelMar Pharmaceuticals, founded in 2010, focuses on the development and commercialization of new cancer therapies.